Drug discovery and development
We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.
The CDK7 inhibitor was identified by a collaborative research team at Imperial College London and Emory University in the US, supported by Cancer Research UK, EPSRC and by the NIHR Imperial BRC. Cancer Research UK funded a research programme at Imperial College London to develop the CDK7 inhibitor – ICEC0942 – as a promising new cancer treatment. In 2016, we licensed ICEC0942, now referred to as samuraciclib or CT7001, as a preclinical compound, to Carrick Therapeutics, with support by Emory University and Imperial Innovations, the Technology Transfer Office of Imperial College London.
“We continue to make great progress in evaluating the combination of samuraciclib and fulvestrant with the dosing of the first patient in the Phase 2b study,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “There is a large unmet need in treatment for women with HR+, HER2- breast cancer, which represents more than two thirds of all new female breast cancer cases. We previously announced data from a single-arm Ph2a study with this combination therapy that demonstrated both clinical activity and tolerability. As such, we are encouraged by the potential of samuraciclib to be a first and best-in-class treatment for women with advanced breast cancer.”
The randomised Phase 2b clinical trial will evaluate the Progression Free Survival benefit of the novel combination of samuraciclib with fulvestrant in comparison to fulvestrant alone for patients with breast cancer that have progressed following treatment with a CDK4/6 inhibitor.
The clinical trial is being conducted with support from Pfizer Ignite, a new end-to-end service for biotech companies with high potential science that leverages the company’s significant R&D capabilities, scale and expertise to accelerate the development of breakthrough therapies.
Carrick maintains full economic ownership and control of samuraciclib and its pipeline. Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT05963984. For additional information on the clinical trial, please contact [email protected].
About samuraciclib (CT7001)
Samuraciclib is the most advanced CDK7 inhibitor in clinical development. Inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and promotes resistance to anti-hormone therapy. Samuraciclib has demonstrated a favourable safety profile and encouraging efficacy in early clinical studies. In addition to the above studies, samuraciclib has further potential in prostate, pancreatic, ovarian and colorectal cancers. Samuraciclib has been granted Fast Track designation from the US Food and Drug Administration (FDA) for use in combination with fulvestrant for the treatment of CDK4/6i resistant HR+, HER2- advanced breast cancer. Carrick is collaborating with Roche, Menarini Group and Arvinas/Pfizer to evaluate novel combinations of samuraciclib with Roche’s oral SERD giredestrant, Menarini Group’s oral SERD elacestrant, and Arvinas/Pfizer’s proteolysis targeting chimera (PROTAC) Estrogen Receptor degrader vepdegestrant (ARV-471) in late-stage CDK4/6i resistant HR+, HER2- metastatic breast cancer.
About Carrick Therapeutics
Carrick Therapeutics is an oncology-focused biopharmaceutical company developing highly differentiated novel therapies that address significant unmet needs. The Company’s lead programme, samuraciclib, is a novel CDK7 inhibitor currently in Phase 2 clinical trials for HR+ breast cancer. Additionally, Carrick is developing CT7439, a novel CDK12/13 inhibitor / Cyclin-K glue-degrader, which is expected to enter a Phase 1 clinical trial in the first half of 2024.
For more information about Carrick Therapeutics, please visit www.carricktherapeutics.com
Carrick contacts
Carrick Therapeutics
Jenny Horsfield, Chief Business Officer
[email protected]
Investors and Media
Luke Heagle, Real Chemistry
[email protected]
